C4 Therapeutics, Inc.

CCCC · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.8%

Institutions102.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$35.95M	$35.58M	$20.76M	$31.10M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$115.22M	-$119.61M	-$139.03M	-$129.53M	-$82.13M	-$60.45M
Operating income as a percentage of revenue.	-320.5%	-336.1%	-669.8%	-416.6%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$104.99M	-$105.32M	-$132.49M	-$128.18M	-$83.89M	-$66.33M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82	$-5.83
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.27	$-1.52	$-2.67	$-2.62	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$74.60M	$55.50M	$126.59M	$29.75M	$76.12M	$181.73M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$359.07M	$349.60M	$376.45M	$430.84M	$506.76M	–
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$0	$11.48M	$10.77M	$10.05M
Everything the company owes — debt, unpaid bills, and other obligations.	$102.49M	$133.62M	$130.34M	$141.61M	$117.16M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$256.59M	$215.99M	$246.11M	$289.23M	$389.61M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$98.69M	-$65.16M	-$106.84M	-$105.94M	-$86.97M	-$67.25M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$607000	$180000	$1.71M	$5.50M	$1.28M	$650000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$99.30M	-$65.34M	-$108.55M	-$111.44M	-$88.24M	-$67.90M

	You	Peer avg
P/E	–	18.7
Revenue Growth	+2.8%	+120.0%
ROE	-48.1%	-58.8%

C4 Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison